Drugs in the Pipeline Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer Publish Date April 13, 2021 Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
Drugs in the Pipeline Mirvetuximab Soravtansine Granted Priority Review for Ovarian Cancer Publish Date May 23, 2022 Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.